Abstract
This Review examines the role of neuroimmune imbalances and their relationship with metabolism and oxidative stress in the development and progression of major depressive disorder (MDD) and suicidal behaviours. We provide a concise overview of the neuroinflammatory environment and indicators of neuronal injury in the central nervous system of individuals with MDD. Furthermore, we explore the evidence for perturbations in both the peripheral and central immune system, T cell activation versus T regulatory cell depletion, intracellular signalling networks including nuclear factor-κB, lipid metabolism and neuroprotection. Last, we examine the mechanisms by which psychological stressors, translocation of Gram-negative bacteria, viral infections such as SARS-CoV-2 and metabolic syndrome can contribute to neuroimmune imbalances and, consequently, the acute phase of MDD.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout




Similar content being viewed by others
References
World Health Organization. Depression. WHO https://www.who.int/news-room/fact-sheets/detail/depression (2023).
Citrome, L. et al. Prevalence, treatment patterns, and stay characteristics associated with hospitalizations for major depressive disorder. J. Affect. Disord. 249, 378–384 (2019).
Cosci, F. & Fava, G. A. Staging of mental disorders: systematic review. Psychother. Psychosom. 82, 20–34 (2012).
Maes, M. et al. Development of a novel staging model for affective disorders using partial least squares bootstrapping: effects of lipid-associated antioxidant defenses and neuro-oxidative stress. Mol. Neurobiol. 56, 6626–6644 (2019).
Maes, M., Kubera, M., Obuchowiczwa, E., Goehler, L. & Brzeszcz, J. Depression’s multiple comorbidities explained by (neuro)inflammatory and oxidative and nitrosative stress pathways. Neuro Endocrinol. Lett. 32, 7–24 (2011).
Athira, K. V. et al. An overview of the heterogeneity of major depressive disorder: current knowledge and future prospective. Curr. Neuropharmacol. 18, 168–187 (2020).
Berk, M. et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 11, 200 (2013).
Maes, M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 19, 11–38 (1995).
Maes, M. & Carvalho, A. F. The compensatory immune-regulatory reflex system (CIRS) in depression and bipolar disorder. Mol. Neurobiol. 55, 8885–8903 (2018).
Herbert, T. B. & Cohen, S. Depression and immunity: a meta-analytic review. Psychol. Bull. 113, 472 (1993).
Blume, J., Douglas, S. D. & Evans, D. L. Immune suppression and immune activation in depression. Brain Behav. Immun. 25, 221–229 (2011).
Ng, A. et al. IL-1β, IL-6, TNF-α and CRP in elderly patients with depression or Alzheimer’s disease: systematic review and meta-analysis. Sci. Rep. 8, 12050 (2018).
Osimo, E. F. et al. Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav. Immun. 87, 901–909 (2020).
Islam, M. R. et al. Evaluation of inflammatory cytokines in drug-naïve major depressive disorder: a systematic review and meta-analysis. Int. J. Immunopathol. Pharmacol. 37, 03946320231198828 (2023).
Jayakumar, S. et al. A systematic review and meta-analysis of the evidence on inflammation in depressive illness and symptoms in chronic and end-stage kidney disease. Psychol. Med. 53, 5839–5851 (2023).
Zhang, Y. et al. Peripheral cytokine levels across psychiatric disorders: a systematic review and network meta-analysis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 125, 110740 (2023).
Köhler, C. A. et al. Peripheral cytokine and chemokine alterations in depression: a meta‐analysis of 82 studies. Acta Psychiat. Scand. 135, 373–387 (2017).
Çakici, N. et al. Altered peripheral blood compounds in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis. Brain Behav. Immun. 88, 547–558 (2020).
Wang, M. et al. Genetically predicted circulating levels of cytokines and the risk of depression: a bidirectional Mendelian-randomization study. Front. Genet. 14, 1242614 (2023).
Mariani, N., Cattane, N., Pariante, C. & Cattaneo, A. Gene expression studies in depression development and treatment: an overview of the underlying molecular mechanisms and biological processes to identify biomarkers. Transl. Psychiatry 11, 354 (2021).
Sørensen, N. V. et al. Immune cell composition in unipolar depression: a comprehensive systematic review and meta-analysis. Mol. Psychiat. 28, 391–401 (2023).
Foley, É. et al. Peripheral blood cellular immunophenotype in depression: a systematic review and meta-analysis. Mol. Psychiatry 28, 1004–1019 (2023).
Zhong, X. et al. Peripheral immunity and risk of incident brain disorders: a prospective cohort study of 161,968 participants. Transl. Psychiatry 13, 382 (2023).
Wittenberg, G. M., Greene, J., Vértes, P. E., Drevets, W. C. & Bullmore, E. T. Major depressive disorder is associated with differential expression of innate immune and neutrophil-related gene networks in peripheral blood: a quantitative review of whole-genome transcriptional data from case-control studies. Biol. Psychiatry 88, 625–637 (2020).
Maes, M. A review on the acute phase response in major depression. Rev. Neurosci. 4, 407–416 (1993).
Smith, K. J., Au, B., Ollis, L. & Schmitz, N. The association between C-reactive protein, interleukin-6 and depression among older adults in the community: a systematic review and meta-analysis. Exp. Gerontol. 102, 109–132 (2018).
Zorrilla, E. P. et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun. 15, 199–226 (2001).
Mac Giollabhui, N., Ng, T. H., Ellman, L. M. & Alloy, L. B. The longitudinal associations of inflammatory biomarkers and depression revisited: systematic review, meta-analysis, and meta-regression. Mol. Psychiatry 26, 3302–3314 (2021).
Cavaleri, D. et al. Blood concentrations of neopterin and biopterin in subjects with depression: a systematic review and meta-analysis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 120, 110633 (2023).
Mazza, M. G., Tringali, A. G. M., Rossetti, A., Botti, R. E. & Clerici, M. Cross-sectional study of neutrophil–lymphocyte, platelet–lymphocyte and monocyte–lymphocyte ratios in mood disorders. Gen. Hosp. Psychiatry 58, 7–12 (2019).
Maes, M., Plaimas, K., Suratanee, A., Noto, C. & Kanchanatawan, B. First episode psychosis and schizophrenia are systemic neuro-immune disorders triggered by a biotic stimulus in individuals with reduced immune regulation and neuroprotection. Cells 10, 2929 (2021).
Almulla, A. F., Abbas Abo Algon, A., Tunvirachaisakul, C., Al-Hakeim, H. K. & Maes, M. T helper-1 activation via interleukin-16 is a key phenomenon in the acute phase of severe, first-episode major depressive disorder and suicidal behaviors. J. Adv. Res. 64, 171–181 (2023).
Rachayon, M., Jirakran, K., Sodsai, P., Sughondhabirom, A. & Maes, M. T cell activation and deficits in T regulatory cells are associated with major depressive disorder and severity of depression. Sci. Rep. 14, 11177 (2024).
Kelley, N., Jeltema, D., Duan, Y. & He, Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int. J. Mol. Sci. 20, 3328 (2019).
Taene, A. et al. The association of major depressive disorder with activation of NLRP3 inflammasome, lipid peroxidation, and total antioxidant capacity. J. Mol. Neurosci. 70, 65–70 (2020).
Kouba, B. R., Gil-Mohapel, J. & Rodrigues, A. L. S. NLRP3 inflammasome: from pathophysiology to therapeutic target in major depressive disorder. Int. J. Mol. Sci. 24, 133 (2022).
Munshi, S. et al. Increased expression of ER stress, inflammasome activation, and mitochondrial biogenesis-related genes in peripheral blood mononuclear cells in major depressive disorder. Mol Psychiatry 30, 574–586 (2025).
Kéri, S., Szabó, C. & Kelemen, O. Expression of Toll-like receptors in peripheral blood mononuclear cells and response to cognitive-behavioral therapy in major depressive disorder. Brain Behav. Immun. 40, 235–243 (2014).
Elovainio, M. et al. Activated immune–inflammatory pathways are associated with long-standing depressive symptoms: evidence from gene-set enrichment analyses in the Young Finns Study. J. Psychiatr. Res. 71, 120–125 (2015).
Cho, J. H., Irwin, M. R., Eisenberger, N. I., Lamkin, D. M. & Cole, S. W. Transcriptomic predictors of inflammation-induced depressed mood. Neuropsychopharmacology 44, 923–929 (2019).
Maes, M. et al. Adverse childhood experiences predict the phenome of affective disorders and these effects are mediated by staging, neuroimmunotoxic and growth factor profiles. Cells 11, 1564 (2022).
Maes, M. et al. Lower degree of esterification of serum cholesterol in depression: relevance for depression and suicide research. Acta Psychiatr. Scand. 90, 252–258 (1994).
Almulla, A. F. et al. Reverse cholesterol transport and lipid peroxidation biomarkers in major depression and bipolar disorder: a systematic review and meta-analysis. Brain Behav. Immun. 113, 374–388 (2023).
Maes, M. et al. Fatty acid composition in major depression: decreased ω3 fractions in cholesteryl esters and increased C20: 4ω6/C20:5ω3 ratio in cholesteryl esters and phospholipids. J. Affect. Disord. 38, 35–46 (1996).
Lin, P. Y., Huang, S. Y. & Su, K. P. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol. Psychiatry 68, 140–147 (2010).
Maes, M., Christophe, A., Bosmans, E., Lin, A. & Neels, H. In humans, serum polyunsaturated fatty acid levels predict the response of proinflammatory cytokines to psychologic stress. Biol. Psychiatry 47, 910–920 (2000).
Maes, M. et al. Lowered ω3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 85, 275–291 (1999).
Carpita, B. et al. Plasma redox and inflammatory patterns during major depressive episodes: a cross-sectional investigation in elderly patients with mood disorders. CNS Spectr. 26, 416–426 (2021).
Liu, T. et al. A meta-analysis of oxidative stress markers in depression. PLoS ONE 10, e0138904 (2015).
Goh, X. X., Tang, P. Y. & Tee, S. F. 8-hydroxy-2′-deoxyguanosine and reactive oxygen species as biomarkers of oxidative stress in mental illnesses: a meta-analysis. Psychiatry Investig. 18, 603–618 (2021).
Palta, P., Samuel, L. J., Miller, E. R. 3rd & Szanton, S. L. Depression and oxidative stress: results from a meta-analysis of observational studies. Psychosom. Med. 76, 12–19 (2014).
Maes, M. et al. Towards a major methodological shift in depression research by assessing continuous scores of recurrence of illness, lifetime and current suicidal behaviors and phenome features. J. Affect. Disord. 350, 728–740 (2024).
Maes, M. et al. Are abnormalities in lipid metabolism, together with adverse childhood experiences, the silent causes of immune-linked neurotoxicity in major depression? Neuro Endocrinol. Lett. 45, 393–408 (2024).
Lucas, K. & Maes, M. Role of the Toll like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol. Neurobiol. 48, 190–204 (2013).
Maes, M., Galecki, P., Chang, Y. S. & Berk, M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 676–692 (2011).
Gałecki, P. et al. Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder. J. Affect. Disord. 129, 175–182 (2011).
Maes, M. & Meltzer, H. in Psychopharmacology: the Fourth Generation of Progress (eds Bloom, F. E. & Kupfer, D. J.) 921–932 (Raven, 1995).
Coppen, A., Brooksbank, B. W., Eccleston, E., Peet, M. & White, S. G. Tryptophan metabolism in depressive illness. Psychol. Med. 4, 164–173 (1974).
Almulla, A. F. et al. The tryptophan catabolite or kynurenine pathway in major depressive and bipolar disorder: a systematic review and meta-analysis. Brain Behav. Immun. Health 26, 100537 (2022).
Maes, M., Leonard, B. E., Myint, A. M., Kubera, M. & Verkerk, R. The new ‘5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35, 702–721 (2011).
Lapin, I. in 1st Congr. Hungarian Pharmacological Society Symp. Pharmacology of Learning and Retention 149–164 (Hungarian Pharmacological Society, 1973).
Almulla, A. F. et al. The tryptophan catabolite or kynurenine pathway in a major depressive episode with melancholia, psychotic features and suicidal behaviors: a systematic review and meta-analysis. Cells 11, 3112 (2022).
Wessa, C. et al. Efficacy of inflammation-based stratification for add-on celecoxib or minocycline in major depressive disorder: protocol of the INSTA-MD double-blind placebo-controlled randomised clinical trial. Brain Behav. Immun. Health 41, 100871 (2024).
Maes, M. et al. The recurrence of illness (ROI) index is a key factor in major depression that indicates increasing immune-linked neurotoxicity and vulnerability to suicidal behaviors. Psychiatry Res. 339, 116085 (2024).
Maes, M. et al. Impairments in peripheral blood T effector and T regulatory lymphocytes in bipolar disorder are associated with staging of illness and anti-cytomegalovirus IgG levels. Mol. Neurobiol. 58, 229–242 (2021).
Maes, M. et al. Simple dysmood disorder, a mild subtype of major depression, is not an inflammatory condition: depletion of the compensatory immunoregulatory system. J. Affect. Disord. 375, 75–85 (2025).
Brinholi, F. F. et al. Increased malondialdehyde and nitric oxide formation, lowered total radical trapping capacity coupled with psychological stressors are strongly associated with the phenome of first-episode mild depression in undergraduate students. Neuroscience 554, 52–62 (2024).
Maes, M. et al. First-episode mild depression in young adults is a pre-proatherogenic condition even in the absence of subclinical metabolic syndrome: lowered lecithin-cholesterol acyltransferase as a key factor. Neuro Endocrinol. Lett. 45, 475–191 (2024).
Maes, M. et al. Major depressive disorder, neuroticism, suicidal behaviors, and depression severity are associated with cytokine networks and their intricate interactions with metabolic syndrome. J. Psychosom. Res. 187, 111951 (2024).
Maes, M., Almulla, A. F., Zhou, B., Algon, A. A. A. & Sodsai, P. In major dysmood disorder, physiosomatic, chronic fatigue and fibromyalgia symptoms are driven by immune activation and increased immune-associated neurotoxicity. Sci. Rep. 14, 7344 (2024).
Maes, M., Scharpé, S., Meltzer, H. Y. & Cosyns, P. Relationships between increased haptoglobin plasma levels and activation of cell-mediated immunity in depression. Biol. Psychiatry 34, 690–701 (1993).
Nässberger, L. & Träskman-Bendz, L. Increased soluble interleukin-2 receptor concentrations in suicide attempters. Acta Psychiatr. Scand. 88, 48–52 (1993).
Maes, M. et al. Biochemical, metabolic and immune correlates of seasonal variation in violent suicide: a chronoepidemiologic study. Eur. Psychiatry 11, 21–33 (1996).
Vasupanrajit, A., Jirakran, K., Tunvirachaisakul, C., Solmi, M. & Maes, M. Inflammation and nitro-oxidative stress in current suicidal attempts and current suicidal ideation: a systematic review and meta-analysis. Mol. Psychiatry 27, 1350–1361 (2022).
Maes, M. et al. Serotonin-immune interactions in major depression: lower serum tryptophan as a marker of an immune-inflammatory response. Eur. Arch. Psychiatry Clin. Neurosci. 247, 154–161 (1997).
Maes, M. et al. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol. Psychiatry 42, 349–358 (1997).
Maes, M. et al. Increased serum IL-6 and IL-1 receptor antagonist concentration in major depression and treatment resistant depression. Cytokine 9, 853–858 (1997).
Mancuso, E. et al. Biological correlates of treatment resistant depression: a review of peripheral biomarkers. Front. Psychiatry 14, 1291176 (2023).
Sánchez-Carro, Y. et al. Importance of immunometabolic markers for the classification of patients with major depressive disorder using machine learning. Prog. Neuropsychopharmacol. Biol. Psychiatry 121, 110674 (2023).
Maes, M. et al. In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatr. Scand. 127, 344–354 (2013).
Kempuraj, D. et al. Neuroinflammation induces neurodegeneration. J. Neurol. Neurosurg. Spine 1, 1003 (2016).
Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481–487 (2017).
Mason, H. D. & McGavern, D. B. How the immune system shapes neurodegenerative diseases. Trends Neurosci. 45, 733–748 (2022).
Gritti, D., Delvecchio, G., Ferro, A., Bressi, C. & Brambilla, P. Neuroinflammation in major depressive disorder: a review of PET imaging studies examining the 18-kDa translocator protein. J. Affect. Disord. 292, 642–651 (2021).
Setiawan, E. et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 72, 268–275 (2015).
Li, H., Sagar, A. P. & Kéri, S. Microglial markers in the frontal cortex are related to cognitive dysfunctions in major depressive disorder. J. Affect. Disord. 241, 305–310 (2018).
Pandey, G. N. Inflammatory and innate immune markers of neuroprogression in depressed and teenage suicide brain. Mod. Trends Pharmacopsychiatry 31, 79–95 (2017).
Shelton, R. C. et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol. Psychiatry 16, 751–762 (2011).
Zhao, X. et al. PTSD, major depression, and advanced transcriptomic age in brain tissue. Depression Anxiety 39, 824–834 (2022).
Rahimian, R., Belliveau, C., Chen, R. & Mechawar, N. Microglial inflammatory-metabolic pathways and their potential therapeutic implication in major depressive disorder. Front. Psychiatry 13, 871997 (2022).
Steiner, J. et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 42, 151–157 (2008).
Yamamoto, M., Sakai, M., Yu, Z., Nakanishi, M. & Yoshii, H. Glial markers of suicidal behavior in the human brain — a systematic review of postmortem studies. Int. J. Mol. Sci. 25, 5750 (2024).
Enomoto, S. & Kato, T. A. Stress mediated microglial hyper-activation and psychiatric diseases [in Japanese]. Brain Nerve 73, 795–802 (2021).
Tonelli, L. H. et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr. Scand. 117, 198–206 (2008).
Böttcher, C. et al. Single-cell mass cytometry of microglia in major depressive disorder reveals a non-inflammatory phenotype with increased homeostatic marker expression. Transl. Psychiatry 10, 310 (2020).
Snijders, G. et al. Distinct non-inflammatory signature of microglia in post-mortem brain tissue of patients with major depressive disorder. Mol. Psychiatry 26, 3336–3349 (2021).
Michel, T. M. et al. Increased xanthine oxidase in the thalamus and putamen in depression. World J. Biol. Psychiatry 11, 314–320 (2010).
Gawryluk, J. W., Wang, J. F., Andreazza, A. C., Shao, L. & Young, L. T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int. J. Neuropsychopharmacol. 14, 123–130 (2011).
Pandey, G. N., Rizavi, H. S., Bhaumik, R. & Ren, X. Innate immunity in the postmortem brain of depressed and suicide subjects: role of Toll-like receptors. Brain Behav. Immun. 75, 101–111 (2019).
Rajkowska, G. & Stockmeier, C. A. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr. Drug. Targets 14, 1225–1236 (2013).
Yao, J. et al. A review of research on the association between neuron-astrocyte signaling processes and depressive symptoms. Int. J. Mol. Sci. 24, 6985 (2023).
Steiner, J. et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J. Neuroinflamm. 8, 94 (2011).
Frick, L. R., Williams, K. & Pittenger, C. Microglial dysregulation in psychiatric disease. Clin. Dev. Immunol. 2013, 608654 (2013).
Czéh, B. & Nagy, S. A. Clinical findings documenting cellular and molecular abnormalities of glia in depressive disorders. Front. Mol. Neurosci. 11, 56 (2018).
Bakunina, N., Pariante, C. M. & Zunszain, P. A. Immune mechanisms linked to depression via oxidative stress and neuroprogression. Immunology 144, 365–373 (2015).
Holmes, S. E. et al. Elevated translocator protein in anterior cingulate in major depression and a role for inflammation in suicidal thinking: a positron emission tomography study. Biol. Psychiatry 83, 61–69 (2018).
Wang, T.-Y. et al. The differential levels of inflammatory cytokines and BDNF among bipolar spectrum disorders. Int. J. Neuropsychopharmacol. 19, pyw012 (2016).
Zhao, Y. F., Verkhratsky, A., Tang, Y. & Illes, P. Astrocytes and major depression: the purinergic avenue. Neuropharmacology 220, 109252 (2022).
Fang, Y. et al. The role and mechanism of NLRP3 inflammasome-mediated astrocyte activation in dehydrocorydaline against CUMS-induced depression. Front. Pharmacol. 13, 1008249 (2022).
Hamidi, M., Drevets, W. C. & Price, J. L. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol. Psychiatry 55, 563–569 (2004).
Pantazatos, S. P. et al. Whole-transcriptome brain expression and exon-usage profiling in major depression and suicide: evidence for altered glial, endothelial and ATPase activity. Mol. Psychiatry 22, 760–773 (2017).
Surget, A. et al. Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology 34, 1363–1380 (2009).
Al-Hakeim, H. K., Twaij, B. A. A., Al-Naqeeb, T. H., Moustafa, S. R. & Maes, M. Neuronal damage and inflammatory biomarkers are associated with the affective and chronic fatigue-like symptoms due to end-stage renal disease. J. Affect. Disord. 347, 220–229 (2024).
Al-Hakeim, H. K., Al-Naqeeb, T. H., Almulla, A. F. & Maes, M. The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with peripheral inflammation, insulin resistance and lowered calcium. J. Affect. Disord. 331, 300–312 (2023).
Ridhaa, M. A. S., Al-Hakeim, H. K., Kahlol, M. K., Al-Naqeeb, T. H. & Maes, M. In children with transfusion-dependent thalassemia, inflammation and neuronal damage biomarkers are associated with affective and chronic fatigue symptoms. Preprint at medRxiv https://doi.org/10.1101/2023.11.21.23298798 (2023).
Almulla, A. F., Maes, M., Zhou, B., Al-Hakeim, H. K. & Vojdani, A. Brain-targeted autoimmunity is strongly associated with long COVID and its chronic fatigue syndrome as well as its affective symptoms. J. Adv. Res. https://doi.org/10.1016/j.jare.2024.11.011 (2024).
Woodburn, S. C., Bollinger, J. L. & Wohleb, E. S. The semantics of microglia activation: neuroinflammation, homeostasis, and stress. J. Neuroinflamm. 18, 258 (2021).
Fan, H. et al. Reactive astrocytes undergo M1 microglia/macrohpages-induced necroptosis in spinal cord injury. Mol. Neurodegener. 11, 14 (2016).
Scheepstra, K. et al. Reporting psychiatric disease characteristics in post-mortem- and biological research. Neurosci. Insights 19, 26331055241252632 (2024).
Huang, M. H. et al. Elevated tumor necrosis factor-alpha receptor subtype 1 and the association with abnormal brain function in treatment-resistant depression. J. Affect. Disord. 235, 250–256 (2018).
Kang, Y. et al. The effect of inflammation markers on cortical thinning in major depressive disorder: a possible mediator of depression and cortical changes. J. Affect. Disord. 348, 229–237 (2024).
Han, K. M. & Ham, B. J. How inflammation affects the brain in depression: a review of functional and structural MRI studies. J. Clin. Neurol. 17, 503–515 (2021).
Chen, M. H. et al. Increased proinflammatory cytokines, executive dysfunction, and reduced gray matter volumes in first-episode bipolar disorder and major depressive disorder. J. Affect. Disord. 274, 825–831 (2020).
Al-Hakeim, H. K. et al. Affective and chronic fatigue symptoms are associated with serum neuronal damage markers in Parkinson’s disease. Sci. Rep. 15, 20647 (2025).
Banks, W. A., Kastin, A. J. & Broadwell, R. D. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 2, 241–248 (1995).
Logsdon, A. F. et al. Inter-alpha inhibitor proteins attenuate lipopolysaccharide-induced blood–brain barrier disruption and downregulate circulating interleukin 6 in mice. J. Cereb. Blood Flow Metab. 40, 1090–1102 (2020).
Varatharaj, A. & Galea, I. The blood–brain barrier in systemic inflammation. Brain Behav. Immun. 60, 1–12 (2017).
Huang, X., Hussain, B. & Chang, J. Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms. CNS Neurosci. Ther. 27, 36–47 (2021).
Nyuyki, K. D. & Pittman, Q. J. Toward a better understanding of the central consequences of intestinal inflammation. Ann. NY Acad. Sci. 1351, 149–154 (2015).
Shang, B. et al. Higher blood–brain barrier permeability in patients with major depressive disorder identified by DCE-MRI imaging. Psychiatry Res. Neuroimag. 337, 111761 (2024).
Medina-Rodriguez, E. M. & Beurel, E. Blood brain barrier and inflammation in depression. Neurobiol. Dis. 175, 105926 (2022).
Wu, S., Yin, Y. & Du, L. Blood–brain barrier dysfunction in the pathogenesis of major depressive disorder. Cell Mol. Neurobiol. 42, 2571–2591 (2022).
Najjar, S., Pearlman, D. M., Devinsky, O., Najjar, A. & Zagzag, D. Neurovascular unit dysfunction with blood–brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence. J. Neuroinflamm. 10, 142 (2013).
Yang, J. et al. New insight into neurological degeneration: inflammatory cytokines and blood–brain barrier. Front. Mol. Neurosci. 15, 1013933 (2022).
Ots, H. D., Tracz, J. A., Vinokuroff, K. E. & Musto, A. E. CD40–CD40L in neurological disease. Int. J. Mol. Sci. 23, 4115 (2022).
Carvalho, C. & Moreira, P. I. Oxidative stress: a major player in cerebrovascular alterations associated to neurodegenerative events. Front. Physiol. 9, 806 (2018).
Wei, C. et al. Brain endothelial GSDMD activation mediates inflammatory BBB breakdown. Nature 629, 893–900 (2024).
Peng, X., Luo, Z., He, S., Zhang, L. & Li, Y. Blood–brain barrier disruption by lipopolysaccharide and sepsis-associated encephalopathy. Front. Cell Infect. Microbiol. 11, 768108 (2021).
Gu, M., Mei, X. L. & Zhao, Y. N. Sepsis and cerebral dysfunction: BBB damage, neuroinflammation, oxidative stress, apoptosis and autophagy as key mediators and the potential therapeutic approaches. Neurotox. Res. 39, 489–503 (2021).
Chen, H. R. et al. Monocytes promote acute neuroinflammation and become pathological microglia in neonatal hypoxic-ischemic brain injury. Theranostics 12, 512–529 (2022).
Torres-Platas, S. G., Cruceanu, C., Chen, G. G., Turecki, G. & Mechawar, N. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav. Immun. 42, 50–59 (2014).
Quan, N. Immune-to-brain signaling: how important are the blood–brain barrier-independent pathways? Mol. Neurobiol. 37, 142–152 (2008).
Reardon, C., Murray, K. & Lomax, A. E. Neuroimmune communication in health and disease. Physiol. Rev. 98, 2287–2316 (2018).
Whooley, M. A. et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 300, 2379–2388 (2008).
Whooley, M. A. Depression and cardiovascular disease: healing the broken-hearted. JAMA 295, 2874–2881 (2006).
Kendler, K. S., Gatz, M., Gardner, C. O. & Pedersen, N. L. A Swedish national twin study of lifetime major depression. Am. J. Psychiatry 163, 109–114 (2006).
Mullins, N. & Lewis, C. M. Genetics of depression: progress at last. Curr. Psychiatry Rep. 19, 43 (2017).
Howard, D. M. et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat. Neurosci. 22, 343–352 (2019).
Maher, B. S. Polygenic scores in epidemiology: risk prediction, etiology, and clinical utility. Curr. Epidemiol. Rep. 2, 239–244 (2015).
Rabinowitz, J. A. et al. Depression polygenic scores are associated with major depressive disorder diagnosis and depressive episode in Mexican adolescents. J. Affect. Disord. Rep. 2, 100028 (2020).
Kappelmann, N. et al. Polygenic risk for immuno-metabolic markers and specific depressive symptoms: a multi-sample network analysis study. Brain Behav. Immun. 95, 256–268 (2021).
Maes, M. et al. Psychomotor retardation, anorexia, weight loss, sleep disturbances, and loss of energy: psychopathological correlates of hyperhaptoglobinemia during major depression. Psychiatry Res. 47, 229–241 (1993).
Wingo, T. S. et al. Brain proteome-wide association study implicates novel proteins in depression pathogenesis. Nat. Neurosci. 24, 810–817 (2021).
Pelegrin, P. P2X7 receptor and the NLRP3 inflammasome: partners in crime. Biochem. Pharmacol. 187, 114385 (2021).
Bufalino, C., Hepgul, N., Aguglia, E. & Pariante, C. M. The role of immune genes in the association between depression and inflammation: a review of recent clinical studies. Brain Behav. Immun. 31, 31–47 (2013).
Wong, M. L., Dong, C., Maestre-Mesa, J. & Licinio, J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol. Psychiatry 13, 800–812 (2008).
Holtzman, S., Abbey, S. E., Chan, C., Bargman, J. M. & Stewart, D. E. A genetic predisposition to produce low levels of IL-10 is related to depressive symptoms: a pilot study of patients with end stage renal disease. Psychosomatics 53, 155–161 (2012).
Moreira, E. G. et al. Lowered PON1 activities are strongly associated with depression and bipolar disorder, recurrence of (hypo)mania and depression, increased disability and lowered quality of life. World J. Biol. Psychiatry 20, 368–380 (2019).
Bortolasci, C. C. et al. Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. J. Affect. Disord. 159, 23–30 (2014).
Kubera, M., Obuchowicz, E., Goehler, L., Brzeszcz, J. & Maes, M. In animal models, psychosocial stress-induced (neuro) inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35, 744–759 (2011).
Maes, M. et al. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 10, 313–318 (1998).
Maes, M. et al. The effects of psychological stress on leukocyte subset distribution in humans: evidence of immune activation. Neuropsychobiology 39, 1–9 (1999).
Steptoe, A., Hamer, M. & Chida, Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav. Immun. 21, 901–912 (2007).
Kuebler, U. et al. Stress-induced modulation of NF-κB activation, inflammation-associated gene expression, and cytokine levels in blood of healthy men. Brain Behav. Immun. 46, 87–95 (2015).
Baumeister, D., Akhtar, R., Ciufolini, S., Pariante, C. M. & Mondelli, V. Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-α. Mol. Psychiatry 21, 642–649 (2016).
Danese, A. & Baldwin, J. R. Hidden wounds? Inflammatory links between childhood trauma and psychopathology. Annu. Rev. Psychol. 68, 517–544 (2017).
Flouri, E., Francesconi, M., Papachristou, E., Midouhas, E. & Lewis, G. Stressful life events, inflammation and emotional and behavioural problems in children: a population-based study. Brain Behav. Immun. 80, 66–72 (2019).
Iob, E., Lacey, R., Giunchiglia, V. & Steptoe, A. Adverse childhood experiences and severity levels of inflammation and depression from childhood to young adulthood: a longitudinal cohort study. Mol. Psychiatry 27, 2255–2263 (2022).
Moraes, J. B. et al. Elevated C-reactive protein levels in women with bipolar disorder may be explained by a history of childhood trauma, especially sexual abuse, body mass index and age. CNS Neurol. Disord. Drug. Targets 16, 514–521 (2017).
Almulla, A. F., Algon, A. A. A. & Maes, M. Adverse childhood experiences and recent negative events are associated with activated immune and growth factor pathways, the phenome of first episode major depression and suicidal behaviors. Psychiatry Res. 334, 115812 (2024).
Maes, M. et al. T cell activation and lowered T regulatory cell numbers are key processes in severe major depressive disorder: effects of recurrence of illness and adverse childhood experiences. J. Affect. Disord. 362, 62–74 (2024).
Moraes, J. B. et al. In major affective disorders, early life trauma predict increased nitro-oxidative stress, lipid peroxidation and protein oxidation and recurrence of major affective disorders, suicidal behaviors and a lowered quality of life. Metab. Brain Dis. 33, 1081–1096 (2018).
Uysal, N. et al. Age-dependent effects of maternal deprivation on oxidative stress in infant rat brain. Neurosci. Lett. 384, 98–101 (2005).
Schiavone, S., Jaquet, V., Trabace, L. & Krause, K. H. Severe life stress and oxidative stress in the brain: from animal models to human pathology. Antioxid. Redox Signal. 18, 1475–1490 (2013).
Maes, M. et al. Adverse childhood experiences and reoccurrence of illness impact the gut microbiome, which affects suicidal behaviours and the phenome of major depression: towards enterotypic phenotypes. Acta Neuropsychiat. 35, 328–345 (2023).
Vyas, N. et al. Systematic review and meta-analysis of the effect of adverse childhood experiences (ACEs) on brain-derived neurotrophic factor (BDNF) levels. Psychoneuroendocrinology 151, 106071 (2023).
Zhang, M., Chen, J., Yin, Z., Wang, L. & Peng, L. The association between depression and metabolic syndrome and its components: a bidirectional two-sample Mendelian randomization study. Transl. Psychiatry 11, 633 (2021).
Khodabandehloo, H., Gorgani-Firuzjaee, S., Panahi, G. & Meshkani, R. Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction. Transl. Res. 167, 228–256 (2016).
Qin, X. et al. PPARγ-mediated microglial activation phenotype is involved in depressive-like behaviors and neuroinflammation in stressed C57BL/6J and ob/ob mice. Psychoneuroendocrinology 117, 104674 (2020).
Marschallinger, J. et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat. Neurosci. 23, 194–208 (2020).
Milanova, I. V., Correa-da-Silva, F., Kalsbeek, A. & Yi, C. X. Mapping of microglial brain region, sex and age heterogeneity in obesity. Int. J. Mol. Sci. 22, 3141 (2021).
Paolicelli, R. C. et al. Microglia states and nomenclature: a field at its crossroads. Neuron 110, 3458–3483 (2022).
Jung, E. S. & Mook-Jung, I. New microglia on the block. Cell Metab. 31, 664–666 (2020).
Hu, Y., Dong, X. & Chen, J. Adiponectin and depression: a meta-analysis. Biomed. Rep. 3, 38–42 (2015).
Rudzki, L. & Maes, M. From “leaky gut” to impaired glia–neuron communication in depression. Adv. Exp. Med. Biol. 1305, 129–155 (2021).
Safadi, J. M., Quinton, A. M. G., Lennox, B. R., Burnet, P. W. J. & Minichino, A. Gut dysbiosis in severe mental illness and chronic fatigue: a novel trans-diagnostic construct? A systematic review and meta-analysis. Mol. Psychiatry 27, 141–153 (2022).
Borkent, J., Ioannou, M., Laman, J. D., Haarman, B. C. M. & Sommer, I. E. C. Role of the gut microbiome in three major psychiatric disorders. Psychol. Med. 52, 1222–1242 (2022).
Aynur, A. & Elif, D. Inhibition of Pseudomonas aeruginosa biofilm formation and motilities by human serum paraoxonase (hPON1). AIMS Microbiol. 2, 388–401 (2016).
Ozer, E. A. et al. Human and murine paraoxonase 1 are host modulators of pseudomonas aeruginosa quorum-sensing. FEMS Microbiol. Lett. 253, 29–37 (2005).
Pirillo, A., Catapano, A. L. & Norata, G. D. in High Density Lipoproteins: From Biological Understanding to Clinical Exploitation (eds von Eckardstein, A. & Kardassis, D.) 483–508 (Springer, 2015).
Al-Sadi, R. et al. Interleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway activation of claudin-2 gene. PLoS ONE 9, e85345 (2014).
Meyer, F., Wendling, D., Demougeot, C., Prati, C. & Verhoeven, F. Cytokines and intestinal epithelial permeability: a systematic review. Autoimmun. Rev. 22, 103331 (2023).
Li, L. et al. Oxidative stress, inflammation, gut dysbiosis: what can polyphenols do in inflammatory bowel disease? Antioxidants 12, 967 (2023).
Gomes, C. et al. Increased root canal endotoxin levels are associated with chronic apical periodontitis, increased oxidative and nitrosative stress, major depression, severity of depression, and a lowered quality of life. Mol. Neurobiol. 55, 2814–2827 (2018).
Vásquez-Pérez, J. M. et al. Is nasal dysbiosis a required component for neuroinflammation in major depressive disorder? Mol. Neurobiol. 62, 2459–2469 (2024).
Al-Hakeim, H. K., Al-Rubaye, H. T., Al-Hadrawi, D. S., Almulla, A. F. & Maes, M. Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study. Mol. Psychiatry 28, 564–578 (2023).
Almulla, A. F., Thipakorn, Y., Zhou, B., Vojdani, A. & Maes, M. Immune activation and immune-associated neurotoxicity in long-COVID: a systematic review and meta-analysis of 103 studies comprising 58 cytokines/chemokines/growth factors. Brain Behav. Immun. 122, 75–94 (2024).
Al-Hakeim, H. K., Al-Rubaye, H. T., Almulla, A. F., Al-Hadrawi, D. S. & Maes, M. Chronic fatigue, depression and anxiety symptoms in long COVID are strongly predicted by neuroimmune and neuro-oxidative pathways which are caused by the inflammation during acute infection. J. Clin. Med. 12, 511 (2023).
Maes, M., Almulla, A. F., Tang, X., Stoyanova, K. & Vojdani, A. From human herpes virus-6 reactivation to autoimmune reactivity against tight junctions and neuronal antigens, to inflammation, depression, and chronic fatigue syndrome due to long COVID. J. Med. Virol. 96, e29864 (2024).
Marzan, D. E. et al. Activated microglia drive demyelination via CSF1R signaling. Glia 69, 1583–1604 (2021).
Liu, J. et al. Neuromodulatory activities of CD4+CD25+ regulatory T cells in a murine model of HIV-1-associated neurodegeneration. J. Immunol. 182, 3855–3865 (2009).
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E. & Mosley, R. L. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease. J. Leukoc. Biol. 82, 1083–1094 (2007).
Stoll, G. & Jander, S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog. Neurobiol. 58, 233–247 (1999).
Zhang, J. et al. IL4-driven microglia modulate stress resilience through BDNF-dependent neurogenesis. Sci. Adv. 7, eabb9888 (2021).
Chen, S. et al. Natural alkaloids from Lotus plumule ameliorate lipopolysaccharide-induced depression-like behavior: integrating network pharmacology and molecular mechanism evaluation. Food Funct. 10, 6062–6073 (2019).
Ising, C. & Heneka, M. T. Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration. Cell Death Dis. 9, 120 (2018).
Milatovic, D., Zaja-Milatovic, S., Montine, K. S., Shie, F. S. & Montine, T. J. Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immune response in vivo. J. Neuroinflamm. 1, 20 (2004).
Author information
Authors and Affiliations
Contributions
The authors contributed equally to all aspects of the article.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Neurology thanks Mu-Hong Chen, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Maes, M., Almulla, A.F., You, Z. et al. Neuroimmune, metabolic and oxidative stress pathways in major depressive disorder. Nat Rev Neurol 21, 473–489 (2025). https://doi.org/10.1038/s41582-025-01116-4
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41582-025-01116-4